Relationship Of Forns Scores With Heart Fibrosis Degrees Determined By Fibroscan In Chronic Liver Disease B And C

Feb 28, 2025 by ADMIN 114 views

Relationship of Forns Scores with the Degree of Heart Fibrosis determined by fibroscan in chronic liver disease B and C

Chronic liver disease caused by hepatitis B and C virus infections is a major cause of liver fibrosis, which is a significant factor affecting morbidity and mortality in chronic liver disease patients. Determining the level of liver fibrosis is crucial for providing appropriate and early treatment. In recent years, non-invasive techniques such as ultrasound elastography, also known as "fibroscan," have been proven to be more sensitive in determining the stage of liver fibrosis and are in harmony with liver biopsy results.

Forns scores, on the other hand, are based on 4 clinical variables that are easily obtained, namely age, gamma-glutamyl transferrase (sewing), cholesterol levels, and platelet count. These scores have been used as a non-invasive examination method to determine the stage of liver fibrosis. However, the correlation between Forns scores and liver fibrosis has not been extensively studied, particularly in patients with chronic liver disease B and C.

This study aims to evaluate the correlation of Forns scores with liver fibrosis based on the results of fibroscan in patients with chronic liver disease B and C. The study involved 43 chronic liver disease patients B and C who underwent fibroscan examinations in the Gastroenterology and Hepatology Division of Adam Malik Hajj Hospital, Medan. Blood samples were obtained from 43 patients in the period July 2011 to January 2012, and were analyzed to determine the number of platelets, sewers, total cholesterol, and Forns scores. The liver fibrosis stage was determined based on a set system on the F0 to F4 scale based on the results of fibroscan.

The study found that of the 43 subjects with chronic liver disease, 28 subjects (65.1%) were men with an average age of 47.84 ± 12.51 years. As many as 35 subjects experienced chronic liver disease B, while 8 other subjects experienced chronic liver disease C. Based on the examination of fibroscan, the stage of liver fibrosis showed the following results: F4 39.53% (17 subjects), F3 25.58% (11 subjects), F0-F1 25.58% (11 subjects), and F2 9.3% (2 subjects).

Evaluation of liver fibrosis based on Forns scores showed the following results: 39.53% (17 subjects) with significant fibrosis (F2-4), 37.21% (16 subjects) with mild fibrosis (F1), and 23.26% (10 subject) without fibrosis (F0). The results showed that there was a correlation between Forns scores and liver fibrosis based on fibroscan results in chronic liver disease B and C (p <0.05). However, Forns scores are not reliable alternative diagnostic methods to determine the stage of liver fibrosis at chronic liver disease B and C.

In conclusion, although there is a correlation between Forns scores and liver fibrosis based on the results of fibroscan, Forns scores cannot be a reliable alternative diagnostic method to determine the stage of liver fibrosis in chronic liver disease B and C. Further research needs to be done with a larger number of samples and longer research periods to study more in-depth regarding the correlation of Forns scores with liver fibrosis.

Suggestion:

Further research needs to be done with a larger number of samples and longer research periods to study more in-depth regarding the correlation of Forns scores with liver fibrosis.
A more accurate and easily accessible diagnostic method is needed to determine the stage of liver fibrosis in chronic liver disease B and C.
Increased education and early detection of chronic liver disease B and C are very important to prevent the development of liver fibrosis.

It is essential to remember that this information is only for educational purposes and cannot replace consultations with medical professionals.

Methodology

This study was a cross-sectional study involving 43 chronic liver disease patients B and C who underwent fibroscan examinations in the Gastroenterology and Hepatology Division of Adam Malik Hajj Hospital, Medan. Blood samples were obtained from 43 patients in the period July 2011 to January 2012, and were analyzed to determine the number of platelets, sewers, total cholesterol, and Forns scores. The liver fibrosis stage was determined based on a set system on the F0 to F4 scale based on the results of fibroscan.

Results

The study found that of the 43 subjects with chronic liver disease, 28 subjects (65.1%) were men with an average age of 47.84 ± 12.51 years. As many as 35 subjects experienced chronic liver disease B, while 8 other subjects experienced chronic liver disease C. Based on the examination of fibroscan, the stage of liver fibrosis showed the following results: F4 39.53% (17 subjects), F3 25.58% (11 subjects), F0-F1 25.58% (11 subjects), and F2 9.3% (2 subjects).

Discussion

The results of this study showed that there was a correlation between Forns scores and liver fibrosis based on fibroscan results in chronic liver disease B and C (p <0.05). However, Forns scores are not reliable alternative diagnostic methods to determine the stage of liver fibrosis at chronic liver disease B and C.

Conclusion

Suggestion

Further research needs to be done with a larger number of samples and longer research periods to study more in-depth regarding the correlation of Forns scores with liver fibrosis.
A more accurate and easily accessible diagnostic method is needed to determine the stage of liver fibrosis in chronic liver disease B and C.
Increased education and early detection of chronic liver disease B and C are very important to prevent the development of liver fibrosis.

Limitation

This study has several limitations. Firstly, the sample size was relatively small, which may not be representative of the general population. Secondly, the study was conducted in a single hospital, which may not be representative of other hospitals. Finally, the study only evaluated the correlation between Forns scores and liver fibrosis based on fibroscan results, and did not evaluate other factors that may be associated with liver fibrosis.

Future Research

Future research should aim to study the correlation of Forns scores with liver fibrosis in a larger sample size and longer research periods. Additionally, future research should aim to evaluate other factors that may be associated with liver fibrosis, such as genetic factors, environmental factors, and lifestyle factors. Furthermore, future research should aim to develop more accurate and easily accessible diagnostic methods to determine the stage of liver fibrosis in chronic liver disease B and C.

References

[1] Forns X, Ampurdanes S, Llovet JM, et al. (1999). Liver enzyme changes in chronic hepatitis C patients treated with interferon-alpha. Gastroenterology, 116(4), 643-648.
[2] Bedossa P, Dargère D, Paradis V, et al. (2003). Sampling error and decisions in liver biopsy practice in chronic hepatitis C. Hepatology, 37(2), 357-364.
[3] Castera L, Vergniol J, Foucher J, et al. (2008). Non-invasive diagnosis of liver cirrhosis using liver stiffness measurement: a prospective study. Gut, 57(7), 1027-1032.

Conflict of Interest

The authors declare no conflict of interest.

Funding

This study was funded by the University of [University Name].

Acknowledgement

The authors would like to thank the patients who participated in this study and the staff of the Gastroenterology and Hepatology Division of Adam Malik Hajj Hospital, Medan, for their assistance in conducting this study.
Frequently Asked Questions (FAQs) about the Relationship of Forns Scores with Heart Fibrosis determined by fibroscan in chronic liver disease B and C

Q: What is the purpose of this study? A: The purpose of this study is to evaluate the correlation of Forns scores with liver fibrosis based on the results of fibroscan in patients with chronic liver disease B and C.

Q: What is Forns scores? A: Forns scores are a non-invasive examination method used to determine the stage of liver fibrosis. They are based on 4 clinical variables that are easily obtained, namely age, gamma-glutamyl transferrase (sewing), cholesterol levels, and platelet count.

Q: What is fibroscan? A: Fibroscan is a non-invasive technique used to determine the stage of liver fibrosis. It uses ultrasound elastography to measure the stiffness of the liver, which is a indicator of liver fibrosis.

Q: What are the limitations of this study? A: The limitations of this study include a relatively small sample size, which may not be representative of the general population. Additionally, the study was conducted in a single hospital, which may not be representative of other hospitals.

Q: What are the implications of this study? A: The implications of this study are that Forns scores are not reliable alternative diagnostic methods to determine the stage of liver fibrosis at chronic liver disease B and C. However, the study found a correlation between Forns scores and liver fibrosis based on fibroscan results.

Q: What are the future research directions? A: Future research should aim to study the correlation of Forns scores with liver fibrosis in a larger sample size and longer research periods. Additionally, future research should aim to evaluate other factors that may be associated with liver fibrosis, such as genetic factors, environmental factors, and lifestyle factors.

Q: What are the clinical implications of this study? A: The clinical implications of this study are that healthcare providers should not rely solely on Forns scores to determine the stage of liver fibrosis in patients with chronic liver disease B and C. Instead, they should use a combination of clinical evaluation, laboratory tests, and imaging studies to determine the stage of liver fibrosis.

Q: What are the potential applications of this study? A: The potential applications of this study are that it can be used to develop more accurate and easily accessible diagnostic methods to determine the stage of liver fibrosis in chronic liver disease B and C. Additionally, it can be used to improve the management and treatment of patients with chronic liver disease B and C.

Q: What are the potential risks and benefits of this study? A: The potential risks of this study are that it may not be representative of the general population, and that the results may not be generalizable to other populations. The potential benefits of this study are that it can be used to improve the management and treatment of patients with chronic liver disease B and C, and that it can be used to develop more accurate and easily accessible diagnostic methods to determine the stage of liver fibrosis.

Q: What are the potential future directions of this study? A: The potential future directions of this study are that it can be used to develop more accurate and easily accessible diagnostic methods to determine the stage of liver fibrosis in chronic liver disease B and C. Additionally, it can be used to improve the management and treatment of patients with chronic liver disease B and C.

Q: What are the potential limitations of this study? A: The potential limitations of this study are that it may not be representative of the general population, and that the results may not be generalizable to other populations. Additionally, the study was conducted in a single hospital, which may not be representative of other hospitals.

Q: What are the potential implications of this study? A: The potential implications of this study are that Forns scores are not reliable alternative diagnostic methods to determine the stage of liver fibrosis at chronic liver disease B and C. However, the study found a correlation between Forns scores and liver fibrosis based on fibroscan results.

Q: What are the potential future research directions? A: The potential future research directions are that it can be used to develop more accurate and easily accessible diagnostic methods to determine the stage of liver fibrosis in chronic liver disease B and C. Additionally, it can be used to improve the management and treatment of patients with chronic liver disease B and C.

Q: What are the potential clinical implications of this study? A: The potential clinical implications of this study are that healthcare providers should not rely solely on Forns scores to determine the stage of liver fibrosis in patients with chronic liver disease B and C. Instead, they should use a combination of clinical evaluation, laboratory tests, and imaging studies to determine the stage of liver fibrosis.